Tong Lu

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 10

Top Topics

Endoplasmic Reticulum

Hodgkin Lymphoma

Diffuse Large B Cell Lymphoma

Top Venues

CPT: pharmacometrics & systems pharmacology

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Rong Deng, Leonid Gibiansky, Tong Lu, Christopher R Flowers, Laurie H Sehn, Qi Liu, Priya Agarwal, Michael Z Liao, Randall Dere, Calvin Lee, Gabriel Man, Jamie Hirata, Chunze Li, Dale Miles
Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study. CPT: pharmacometrics & systems pharmacology 13 (6) (2024)
Rong Deng, Leonid Gibiansky, Tong Lu, Christopher R Flowers, Laurie H Sehn, Qi Liu, Priya Agarwal, Michael Z Liao, Randall Dere, Calvin Lee, Gabriel Man, Jamie Hirata, Chunze Li, Dale Miles
Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study. CPT: pharmacometrics & systems pharmacology 13 (6) (2024)
Rong Deng, Leonid Gibiansky, Tong Lu, Christopher R Flowers, Laurie H Sehn, Qi Liu, Priya Agarwal, Michael Z Liao, Randall Dere, Calvin Lee, Gabriel Man, Jamie Hirata, Chunze Li, Dale Miles
Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study. CPT: pharmacometrics & systems pharmacology 13 (6) (2024)
Rong Deng, Leonid Gibiansky, Tong Lu, Christopher R Flowers, Laurie H Sehn, Qi Liu, Priya Agarwal, Michael Z Liao, Randall Dere, Calvin Lee, Gabriel Man, Jamie Hirata, Chunze Li, Dale Miles
Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study. CPT: pharmacometrics & systems pharmacology (2024)
Tong Lu, Victor Poon, Logan Brooks, Erick Velasquez, Eric Anderson, Kyle Baron, Jin Yan Jin, Matts Kagedal
gPKPDviz: A flexible R Shiny tool for pharmacokinetic/pharmacodynamic simulations using mrgsolve. CPT: pharmacometrics & systems pharmacology (2023)
John Francis Seymour, Thomas J Kipps, Barbara F Eichhorst, James D'Rozario, Carolyn J Owen, Sarit Assouline, Nicole Lamanna, Tadeusz Robak, Javier de laSerna, Ulrich Jäger, Guillaume Cartron, Marco Montillo, Clemens Mellink, Brenda Chyla, Anesh Panchal, Tong Lu, Jenny Q Wu, Yanwen Jiang, Marcus Lefebure, Michelle Boyer, Arnon P Kater
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab. Blood 140 (8) (2022)
Anita Moein, Tong Lu, Siv Jonsson, Jakob Ribbing, Nastya Kassir, Wenhui Zhang, Gizette Sperinde, Rong Zhang, Meina T Tang, Young S Oh, René Bruno, Rui Zhu
Population pharmacokinetic analysis of etrolizumab in patients with moderately-to-severely active ulcerative colitis. CPT: pharmacometrics & systems pharmacology 11 (9) (2022)
Othman Al-Sawaf, Can Zhang, Tong Lu, Michael Z Liao, Anesh Panchal, Sandra Robrecht, Travers Ching, Maneesh Tandon, Anna-Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Sebastian Böttcher, Karl-Anton Kreuzer, Brenda Chyla, Dale Miles, Clemens-Martin Wendtner, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer
Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Tong Lu, Yujie Yang, Jin Y Jin, Matts Kågedal
Analysis of Longitudinal-Ordered Categorical Data for Muscle Spasm Adverse Event of Vismodegib: Comparison Between Different Pharmacometric Models. CPT: pharmacometrics & systems pharmacology 9 (2) (2020)
Dan Lu, Tong Lu, Leonid Gibiansky, Xiaobin Li, Chunze Li, Priya Agarwal, Colby S Shemesh, Rong Shi, Randall C Dere, Jamie Hirata, Dale Miles, Pascal Chanu, Sandhya Girish, Jin Yan Jin
Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non-Hodgkin Lymphoma. CPT: pharmacometrics & systems pharmacology 9 (1) (2019)